The state of Victoria (Australia) and Korea have signed a Memorandum of Understanding (MoU) to collaborate on mRNA vaccine research. The partnership will boost the mRNA capabilities of both jurisdictions. 

The MoU is between mRNA Victoria and the Korea Health Industry Development Institute (KHIDI). KHIDI drives Korea’s innovation plans for pharmaceuticals, medical devices and medical services. The MoU will bring together Victoria’s biotech research expertise with Korea’s biomanufacturing specialisation.

Victoria and Korea will exchange information and develop linkages between industry, research and government organisations. They will seek opportunities for joint early-stage; RNA research; clinical trials; and investment into the development and manufacture of new RNA-based therapies and vaccines. The MoU also considers government-to-government collaboration on policies for fostering innovation and supporting local industry development. These include cooperating on capability-building initiatives in Victoria and Korea.

"We hope the signing of this MoU will bring more collaborations in the RNA-based technology field between two organisations for securing new healthcare technologies," says Dr Young-ok Kim, Executive Director of the Korea Health Industry Development Institute. "Together, we can contribute to the development of the global RNA ecosystem and future pandemic response."